A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens
for subjects with multiple myeloma who have received all available approved treatment options
and may therefore be considered candidates for palliative care.